Bone health in the prostate cancer patient receiving androgen deprivation therapy: a review of present and future management options.
Osteoporosis and bone fractures are frequently overlooked complications of androgen deprivation therapy in men with nonmetastatic prostate cancer. All such patients should have their bone mineral density (BMD) monitored and be offered preventive measures, such as calcium and vitamin D supplementation; patients with low BMD should be offered treatment. Several agents, including bisphosphonates, are available (although this use is currently off-label), and upcoming treatments, such as denosumab and toremifene, have shown promise in reducing fracture risk in these patients.
Egerdie
Blair
B
Vice President Medical, St. Mary's General Hospital, Adjunct Professor of Urology, The University of Western Ontario, London, ON;
Saad
Fred
F